Spread of tick-borne encephalitis virus in the Netherlands Every year about 1.5 million ticks bite someone in the Netherlands, especially between March and October. Most people will not get sick of that.
Population screening programmes temporarily on hold Due to the novel coronavirus (COVID-19) outbreak, the health care capacity in the Netherlands is expected to come under severe pressure in the coming period.
Towards a sustainable, healthy future for everyone: EU project INHERIT offers policy solutions Today, on 10 December a policy toolkit will be presented at the final conference of the European four-year research project INHERIT.
Environmental radioactivity in the Netherlands : Results in 2017 RIVM reports annually on the level of radioactivity that occurs under normal circumstances in the environment and food.
A guide for the safe reuse of diaper and incontinence materials RIVM has developed a step-by-step plan for the safe reuse of diapers and incontinence material. This plan provides recyclers and licensing authorities with tools to carry out a risk assessment.
Emphasising safety and sustainability in circular design A stronger focus on safety, health and sustainability is needed in designing circular products. When basic resources are re-used in new products, health risks should be avoided.
Health and Well-being through Effective Blue-Green Space Design and Governance During World Water Week (August 26 – 31, 2018), the Dutch National Institute for Public Health and the Environment, RIVM, is facilitating a session on Health and Well-being through effective Blue-G
Animal-free innovations in safety assessment of chemicals How can the process of validation, acceptance and use of animal-free innovative approaches to assess the safety of chemicals be facilitated?
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.